{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T12:23:26Z","timestamp":1787228606037,"version":"build-2736575974"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2022M710757"],"award-info":[{"award-number":["2022M710757"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82202995"],"award-info":[{"award-number":["82202995"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103369"],"award-info":[{"award-number":["82103369"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472866"],"award-info":[{"award-number":["82472866"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.tranon.2026.102887","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T09:32:46Z","timestamp":1782984766000},"page":"102887","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Integrated multi-omics and single-cell analysis of galectins and immune associations in triple-negative breast cancer"],"prefix":"10.1016","volume":"71","author":[{"given":"Peng","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongrui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gen-Hong","family":"Di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Ming","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3824-3300","authenticated-orcid":false,"given":"Yue","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2026.102887_bib0001","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","article-title":"Breast cancer","volume":"397","author":"Loibl","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.tranon.2026.102887_bib0002","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.tranon.2026.102887_bib0003","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer \u2014 Expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102887_bib0004","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071674","article-title":"Advances in systemic therapies for triple negative breast cancer","volume":"381","author":"Leon-Ferre","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.tranon.2026.102887_bib0005","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2026.102887_bib0006","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.tranon.2026.102887_bib0007","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.tibs.2016.11.003","article-title":"Translating the \u2018sugar code\u2019 into immune and vascular signaling programs","volume":"42","author":"Cerliani","year":"2017","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.tranon.2026.102887_bib0008","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.molmed.2018.02.008","article-title":"Untangling Galectin-driven regulatory circuits in autoimmune inflammation","volume":"24","author":"Toscano","year":"2018","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.tranon.2026.102887_bib0009","article-title":"Sweetening the hallmarks of cancer: galectins as multifunctional mediators of tumor progression","volume":"217","author":"Girotti","year":"2019","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tranon.2026.102887_bib0010","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41573-023-00636-2","article-title":"Targeting galectin-driven regulatory circuits in cancer and fibrosis","volume":"22","author":"Mari\u00f1o","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tranon.2026.102887_bib0011","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1158\/1078-0432.CCR-18-3870","article-title":"Impact of galectins in resistance to anticancer therapies","volume":"26","author":"Navarro","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102887_bib0012","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abl8247","article-title":"In vivo multidimensional CRISPR screens identify Lgals2 as an immunotherapy target in triple-negative breast cancer","volume":"8","author":"Ji","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.tranon.2026.102887_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2019.02.001","article-title":"Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies","volume":"35","author":"Jiang","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tranon.2026.102887_bib0014","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.tranon.2026.102887_bib0015","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adj7808","article-title":"Interferon-induced senescent CD8+ T cells reduce anti-PD1 immunotherapy efficacy in early triple-negative breast cancer","volume":"17","author":"Fu","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tranon.2026.102887_bib0016","doi-asserted-by":"crossref","first-page":"16910","DOI":"10.1073\/pnas.1009843107","article-title":"Allele-specific copy number analysis of tumors","volume":"107","author":"Van Loo","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.tranon.2026.102887_bib0017","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2011-12-4-r41","article-title":"GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers","volume":"12","author":"Mermel","year":"2011","journal-title":"Genome Biol."},{"key":"10.1016\/j.tranon.2026.102887_bib0018","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/jnci\/djad154","article-title":"Genomic alterations affecting tumor-infiltrating lymphocytes and PD-L1 expression patterns in triple-negative breast cancer","volume":"115","author":"Wang","year":"2023","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.tranon.2026.102887_bib0019","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/PAI.0000000000000594","article-title":"Development of a PD-L1 complementary diagnostic immunohistochemistry assay (SP142) for Atezolizumab","volume":"27","author":"Vennapusa","year":"2019","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1016\/j.tranon.2026.102887_bib0020","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tranon.2026.102887_bib0021","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","article-title":"Determining cell type abundance and expression from bulk tissues with digital cytometry","volume":"37","author":"Newman","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.tranon.2026.102887_bib0022","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tranon.2026.102887_bib0023","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nbt.4096","article-title":"Integrating single-cell transcriptomic data across different conditions, technologies, and species","volume":"36","author":"Butler","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.tranon.2026.102887_bib0024","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","article-title":"Fast, sensitive and accurate integration of single-cell data with Harmony","volume":"16","author":"Korsunsky","year":"2019","journal-title":"Nat. Methods"},{"key":"10.1016\/j.tranon.2026.102887_bib0025","doi-asserted-by":"crossref","first-page":"D870","DOI":"10.1093\/nar\/gkac947","article-title":"CellMarker 2.0: an updated database of manually curated cell markers in human\/mouse and web tools based on scRNA-seq data","volume":"51","author":"Hu","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.tranon.2026.102887_bib0026","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13045-023-01497-3","article-title":"Recent advances in targeted strategies for triple-negative breast cancer","volume":"16","author":"Zhu","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.tranon.2026.102887_bib0027","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/nature02502","article-title":"Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin-\u03b1 secretion in vitro","volume":"429","author":"Ozaki","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.tranon.2026.102887_bib0028","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.4049\/jimmunol.173.6.3825","article-title":"Human Galectin-2: novel inducer of T cell apoptosis with distinct profile of caspase Activation","volume":"173","author":"Sturm","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.tranon.2026.102887_bib0029","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012806","article-title":"Stimulation of collateral vessel growth by inhibition of galectin 2 in mice using a single-domain llama-derived antibody","volume":"8","author":"Hollander","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.tranon.2026.102887_bib0030","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41388-020-01523-5","article-title":"Genome-wide CRISPR screen identifies LGALS2 as an oxidative stress-responsive gene with an inhibitory function on colon tumor growth","volume":"40","author":"Li","year":"2021","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.tranon.2026.102887_bib0031","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.21037\/gs-22-452","article-title":"LGALS2 suppresses the progression of papillary thyroid carcinoma by regulating the PI3K\/AKT pathway","volume":"11","author":"Xu","year":"2022","journal-title":"Gland Surg."},{"key":"10.1016\/j.tranon.2026.102887_bib0032","doi-asserted-by":"crossref","first-page":"7035","DOI":"10.1158\/1078-0432.CCR-11-1462","article-title":"Serum Galectin-2, -4, and -8 are greatly increased in colon and breast cancer patients and promote cancer cell adhesion to blood vascular endothelium","volume":"17","author":"Barrow","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102887_bib0033","first-page":"2301","article-title":"Overexpression of galectin2 (LGALS2) predicts a better prognosis in human breast cancer","volume":"14","author":"Chetry","year":"2022","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.tranon.2026.102887_bib0034","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-024-02126-4","article-title":"Deciphering the role of LGALS2: insights into tertiary lymphoid structure-associated dendritic cell activation and immunotherapeutic potential in breast cancer patients","volume":"23","author":"Li","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.tranon.2026.102887_bib0035","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1016\/j.gendis.2022.05.020","article-title":"A new emerging target in cancer immunotherapy: galectin-9 (LGALS9)","volume":"10","author":"Lv","year":"2023","journal-title":"Genes Dis."},{"key":"10.1016\/j.tranon.2026.102887_bib0036","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1158\/1078-0432.CCR-04-0861","article-title":"Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer","volume":"11","author":"Irie","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102887_bib0037","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.it.2011.05.003","article-title":"Emerging Tim-3 functions in antimicrobial and tumor immunity","volume":"32","author":"Sakuishi","year":"2011","journal-title":"Trends Immunol."},{"key":"10.1016\/j.tranon.2026.102887_bib0038","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ebiom.2017.07.018","article-title":"The Tim-3-galectin-9 secretory pathway is involved in the immune escape of Human acute myeloid leukemia cells","volume":"22","author":"Gon\u00e7alves Silva","year":"2017","journal-title":"eBioMedicine"},{"key":"10.1016\/j.tranon.2026.102887_bib0039","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01594","article-title":"The Tim-3-Galectin-9 pathway and its regulatory mechanisms in Human breast cancer","volume":"10","author":"Yasinska","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tranon.2026.102887_bib0040","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s41467-021-21099-2","article-title":"Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy","volume":"12","author":"Yang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tranon.2026.102887_bib0041","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40364-025-00759-1","article-title":"Multifaceted roles of galectins: from carbohydrate binding to targeted cancer therapy","volume":"13","author":"Zhang","year":"2025","journal-title":"Biomark. Res."},{"key":"10.1016\/j.tranon.2026.102887_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2024.101117","article-title":"Galectin-3 secreted by triple-negative breast cancer cells regulates T cell function","volume":"60","author":"Raiter","year":"2025","journal-title":"Neoplasia"},{"key":"10.1016\/j.tranon.2026.102887_bib0043","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011445","article-title":"Tumor-secreted galectin-3 suppresses antitumor response by inducing IL-10+ B cells","volume":"13","author":"Zheng","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.tranon.2026.102887_bib0044","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41420-023-01500-3","article-title":"RNF8 enhances the sensitivity of PD-L1 inhibitor against melanoma through ubiquitination of galectin-3 in stroma","volume":"9","author":"Guo","year":"2023","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.tranon.2026.102887_bib0045","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","article-title":"Macrophage diversity enhances tumor progression and metastasis","volume":"141","author":"Qian","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.tranon.2026.102887_bib0046","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1146\/annurev-immunol-110519-071134","article-title":"Insights gained from single-cell analysis of immune cells in the tumor microenvironment","volume":"39","author":"Ren","year":"2021","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.tranon.2026.102887_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2021.04.014","article-title":"Conserved pan-cancer microenvironment subtypes predict response to immunotherapy","volume":"39","author":"Bagaev","year":"2021","journal-title":"Cancer Cell"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193652332600224X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193652332600224X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:23:40Z","timestamp":1787225020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S193652332600224X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":47,"alternative-id":["S193652332600224X"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102887","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrated multi-omics and single-cell analysis of galectins and immune associations in triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102887","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102887"}}